Global Diabetic Foot Ulcers Treatment Overview
Diabetic foot ulcers treatment market accounted for US$ 3.6 billion in 2020 and is estimated to be US$ 7.4 billion by 2030 and is anticipated to register a CAGR of 7.50%.
Diabetic Foot Ulcers are very common condition related to poor controlled diabetes, which results in tissue breaking mainly in foot. Diabetic Foot Ulcers are very common condition in diabetic patients. According to Centers of Disease Control and Prevention around 25% of people are suffering from diabetes experience diabetic foot ulcers once in their life. Diabetic foot ulcer is a very common condition related to diabetes mellitus. Patients suffering from diabetes are highly prone to suffer from this condition. According to the data published by Centers of Disease Control and Prevention, diabetic foot ulcers affects around 25% of patients suffering from diabetes at least once in their lifetime. The most common causes of diabetic foot ulcers are poor circulation, high blood sugar (hyperglycemia), nerve damage, irritated or wounded feet. Currently, key players involved in the diabetic ulcers has launches a number of treatment medication and devices such as wound care dressings, biologics, and diabetic ulcers treatment devices etc. for the treatment of this condition.
Global Diabetic Foot Ulcers Treatment Drivers & Restraints
High prevalence of diabetes
High prevalence of diabetes is expected to be a major factor driving the need for diabetic foot ulcers medication and fueling its market growth in near future. For instance, As per the data published by National Center for Biotechnology Information in 2017, by diabetes mellitus (DM) is one of the most common metabolic disorder, it was estimated that around 2–5% of the population in Europe are suffering from diabetes mellitus and around 20% of the global. Launches of novel products for the treatment of diabetic foot ulcers are expected to boost the market growth in near future. For instance, in 2016, Integra LifeSciences Corporation received U.S. Food and Drug Administration approval for a new indication of its Omnigraft Dermal Regeneration Matrix for the treatment of certain diabetic foot ulcers. In 2015, NovaLead Pharma launched its new drug Galnobax- a topical gel indicated for the treatment of diabetic foot ulcer.
Presence of robust pipeline
Furthermore, presence of robust pipeline of novel diabetic ulcers treatment products is expected to drive market growth over the forecast period. For instance, in 2014, Adocia SA, a clinical-stage biotechnology company, initiated Phase III study of BioChaperone PDGF-BB, a novel formulation of Platelet Derived Growth Factor (PDGF-BB) for the treatment of diabetic foot ulcers in India. In 2016, Adocia SA announced positive results of Phase 3 clinical trial of BioChaperone PDGF (BC PDGF). Launches of such under development drugs in emerging economies are expected to significantly fuel market growth in near future.
Global Diabetic Foot Ulcers Treatment Segmentations & Regional Insights
The diabetic foot ulcers treatment market has been segmented on the basis of product type, ulcers type, end users, and region.
The product type segment includes wound care dressings (foam dressing, hydrocolloid dressing, hydrogel dressing, alginate dressing, and other dressing), biologics (growth factors, skin graft, and skin substitutes), wound care therapy devices (negative pressure wound devices, hyperbaric oxygen therapy, and other wound care therapy devices), and others.
On the basis of ulcers type target market is categorized as neuropathic ulcers, and neuro-ischemic ulcers.
On the basis of distribution channel, the diabetic foot ulcers treatment market has been segmented in hospital, clinics, ambulatory surgical center, and homecare setting.
Regional Insights:
On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions.
Attribute |
Details |
Base year for estimation |
2020 |
Forecast period |
2020 – 2029 |
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
Market Segmentation |
By Product Type- Wound Care Dressings (Foam Dressing, Hydrocolloid Dressing, Hydrogel Dressing, Alginate Dressing, and Other Dressing), Biologics (Growth factors, Skin Graft, and Skin Substitutes), Wound Care Therapy Devices (Negative Pressure Wound Devices, Hyperbaric Oxygen Therapy, and Other Wound Care Therapy Devices), and Others By Ulcer Type- Neuropathic Ulcers and Neuro-Ischemic Ulcers By End-User- Disease Diagnosis, And Research And Drug Discovery |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Detailed Segmentation:
Diabetic Foot Ulcers Treatment Market, By Product Type:
Wound Care Dressings
- Foam Dressing
- Hydrocolloid Dressing
- Hydrogel Dressing
- Alginate Dressing
- Other Dressing
Biologics
- Growth factors
- Skin Graft and Skin Substitutes
Wound Care Therapy Devices
- Negative Pressure Wound Devices
- Hyperbaric Oxygen Therapy
- and Other Wound Care Therapy Devices
Others
Diabetic Foot Ulcers Treatment Market, By Ulcers Type:
- Neuropathic Ulcers
- Others
- Neuro-Ischemic Ulcers
Diabetic Foot Ulcers Treatment Market, By End User:
- Hospital
- Homecare Setting
- Ambulatory Surgical Center
- Clinics
Diabetic Foot Ulcers Treatment Market, By Region:
- North America
- North America Diabetic Foot Ulcers Treatment Market, By Product Type
- North America Diabetic Foot Ulcers Treatment Market, By Ulcers Type
- North America Diabetic Foot Ulcers Treatment Market, By End User
- North America Diabetic Foot Ulcers Treatment Market, By Country
U.S.
Canada
- Europe
- Europe Diabetic Foot Ulcers Treatment Market, By Product Type
- Europe Diabetic Foot Ulcers Treatment Market, By Ulcers Type
- Europe Diabetic Foot Ulcers Treatment Market, By End User
- Europe Diabetic Foot Ulcers Treatment Market, By Country
Germany
UK
France
Russia
Italy
Switzerland
Sweden
Rest of Europe
- Asia-Pacific
- Asia-Pacific Diabetic Foot Ulcers Treatment Market, By Product Type
- Asia Pacific Diabetic Foot Ulcers Treatment Market, By Ulcers Type
- Asia-Pacific Diabetic Foot Ulcers Treatment Market, By End User
- Asia-Pacific Diabetic Foot Ulcers Treatment Market, By Country
Ø China
Ø India
Ø Australia & New Zealand
Ø Japan
Ø South Korea
Ø Rest of Asia Pacific
- Latin America
- Latin AmericaDiabetic Foot Ulcers Treatment Market, By Product Type
- Latin America Diabetic Foot Ulcers Treatment Market, By Ulcers Type
- Latin America Diabetic Foot Ulcers Treatment Market, By End User
- Latin AmericaDiabetic Foot Ulcers Treatment Market, By Country
Ø Brazil
Ø Mexico
Ø Argentina and Chile
Ø Rest of Latin America
- Middle East
- Middle East Diabetic Foot Ulcers Treatment Market, By Product Type
- Middle East Diabetic Foot Ulcers Treatment Market, By Ulcers Type
- Middle East Diabetic Foot Ulcers Treatment Market, By End User
- Middle East Diabetic Foot Ulcers Treatment Market, By Country
Ø GCC
Ø Israel
Ø Saudi Arabia
Ø UAE
Ø Rest of Middle East
- Africa
- Africa Diabetic Foot Ulcers Treatment Market, By Product Type
- Africa Diabetic Foot Ulcers Treatment Market, By Ulcers Type
- Africa Diabetic Foot Ulcers Treatment Market, By End User
- Africa Diabetic Foot Ulcers Treatment Market, By Country
Ø North Africa
Ø Central Africa
Ø South Africa
Global Diabetic Foot Ulcers Treatment Competitive Landscape & Key Players
Key players operating in the diabetic foot ulcers treatment market includes, Medtronic Plc,Coloplast A/S, Acelity L.P. Inc., 3M Healthcare, Smith & Nephew Plc., ConvaTecInc, B.BraunMelsungen AG, and Mölnlycke Health Care.
Global Diabetic Foot Ulcers Treatment Company Profile
- Medtronic Plc.
- Mölnlycke Health Care
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies Overview
- B.BraunMelsungen AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies Overview
- ConvaTec Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies Overview
- Smith & Nephew Plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies Overview
- 3M Healthcare
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies Overview
- Acelity L.P. Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies Overview
- Coloplast A/S
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies Overview
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies Overview
- Mölnlycke Health Care
Global Diabetic Foot Ulcers Treatment Highlights
FAQs
The diabetic foot ulcers treatment market has been segmented on the basis of product type, ulcers type, end users, and region.
More high prevalence of diabetes in key regions is also expected to drastically increase demand for diabetic foot ulcers medication
Lack of awareness and high cost of drug might hampers the market
Key players operating in the diabetic foot ulcers treatment market includes, Medtronic Plc,Coloplast A/S, Acelity L.P. Inc., 3M Healthcare, Smith & Nephew Plc., ConvaTecInc, B.BraunMelsungen AG, and Mölnlycke Health Care.
North America is expected to account major market share as compared to that of other regions.